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EGFR = epidermal growth factor receptor; ER = estrogen receptor; ERK = extracellular signal-regulated kinase; MAPK = mitogen-activated protein
kinase; PI3K = phosphoinositol 3-kinase; STI = signal transduction inhibitor.
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Introduction
Although the mechanisms that underlie endocrine resistance
in breast cancer are complex, their investigation has potential
to reveal new targets to treat or even prevent this undesirable
state. Of particular interest are growth factor receptor kinase
cascades; there are experimental data implicating increased
signalling through these pathways in both de novo and
acquired resistance to tamoxifen. Various estrogen receptor
(ER)-negative and ER-positive de novo tamoxifen resistant
cell models have elevated epidermal growth factor receptor
(EGFR)/HER2 signalling. In acquired tamoxifen resistance,
models such as TAMR are equally persuasive in implicating
EGFR, HER2 and insulin-like growth factor-1 receptor, and
activity of extracellular signal-regulated kinase (ERK)1/2
mitogen-activated protein kinase (MAPK) and phospho-
inositol 3-kinase (PI3K)/AKT [1]. Signal transduction
inhibitors (STIs) such as the EGFR selective tyrosine kinase
inhibitor gefitinib and agents that target the increased
downstream intracellular kinases can be growth inhibitory in
both resistance settings. As such, clinical trials are underway
with STI monotherapy in recurrent tamoxifen resistant,
advanced/metastatic and ER-negative breast cancer.
Further experimental studies have demonstrated that the
growth factor receptor kinases, in addition to their direct
stimulation of proliferation/survival signals, interplay with ER
to promote tamoxifen resistant growth. Both genomic and
nongenomic mechanisms of crosstalk have been implicated.
In the acquired TAMR model, EGFR/HER2 primed MAPK
and AKT phosphorylate nuclear ER AF-1 residues, allowing
coactivator recruitment that enhances the transcriptional
activity of the tamoxifen–ER complex and promotes growth
[1]. In MCF-7/HER2-18 cells [2], tamoxifen activates plasma
membrane ER, triggering HER2/MAPK activity, phosphory-
lation of nuclear ER and activation of its coactivator AIB1.
Such close interplay has provided considerable rationale for
further clinical trials employing STIs in combination with
various antihormonal strategies [3]. However, several burning
issues remain.
Are growth factor receptor kinases prominent
in clinical acquired resistance to tamoxifen,
and is there any evidence of crosstalk with ER?
If STIs are to be valuable in patients, then it is critical that
model system data are underpinned by equivalent demon-
stration of the target signalling pathways in clinical breast
cancer. Consistent with experimental observations, ER-
negative tumours do commonly exhibit enhanced
EGFR/HER2 expression and activation of ERK1/2 MAPK
and AKT, whereas (more controversially) ER-positive
patients who are de novo resistant to tamoxifen can also
exhibit such signalling increases versus responsive disease
[1]. However, deciphering growth factor receptor kinase
pathways at the time of acquisition of tamoxifen resistance
has proved notoriously problematic in clinical material
because of the difficulty in obtaining paired samples before
tamoxifen administration and subsequently on relapse. Some
but not all of the limited data available are compatible with in
vitro observations demonstrating growth factor receptor
kinase pathway functionality in acquired resistance.
Increases in several components of EGFR/MAPK signalling,
the alternative MAPK Jun kinase [4] and HER2 [5] have
been shown on progression, including studies using
sequential breast cancer samples taken during tamoxifen
treatment of ER-positive primary elderly patients [1].
However, such increases can be quite modest, requiring
sensitive assays for accurate measurement both of
expression and signalling activity. Not surprisingly, therefore,
the magnitude of the pathways in clinical acquired
resistance remains highly controversial.
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A recent report from Guttierez and coworkers [6] is important
because it assembles further supportive clinical evidence of
prominent HER2/kinase signalling in acquired resistance
using paired breast cancer samples taken before adjuvant
tamoxifen treatment and on progression. In tumours retaining
ER, HER2 overexpression and/or amplification occurred at
the time of tamoxifen relapse in 11% of HER2-negative
tumours. Increased signalling through the stress-activated
MAPK p38 and ERK1/2 MAPK were also apparent on
recurrence. Increases in HER2 and p38 activity were similarly
noted in acquired tamoxifen resistant xenografts. Interestingly,
there were correlations between ER and activity of the two
kinases in the clinical relapse material, supportive of
ER–kinase crosstalk and hence targeting of the contributory
pathways following acquisition of tamoxifen resistance.
The mechanism of kinase interplay with ER now requires
deciphering, using antibodies specific for ER phosphorylation
and coactivators. However, there remains an urgent
requirement for access to sequential clinical tumour material
during treatment and at relapse if this quest to decipher
growth factor receptor-kinases and their cross-talk with ER is
to continue. Collection of circulating tumour cells may provide
a useful resource in this regard. As proof of principle, Meng
and coworkers [7] were able to use this approach to reveal
modest HER2 gene amplification acquired by some HER2-
negative patients during progression on chemotherapy, with
subsequent responses to herceptin-containing therapy.
Is growth factor receptor kinase crosstalk
with ER contributory in acquired resistance to
oestrogen deprivation and can it be
therapeutically targeted?
In antihormone responsive models, STIs improve the actions
of endocrine strategies and delay development of resistance.
STIs also enhance the inhibitory effects of endocrine agents
in acquired tamoxifen resistant TAMR and ER positive de
novo tamoxifen resistant MCF-7/HER2-18 cell models [1].
Indeed, in the latter model STIs can recover tamoxifen
sensitivity [2]. Such observations provide a rationale for
clinical studies exploring combination treatment of STIs with
antioestrogens or aromatase inhibitors [3]. However, given
that aromatase inhibitors are increasingly a frontline treatment
in the management of ER-positive postmenopausal breast
cancer, a key issue is whether the value of combination
treatment extends to cells that are refractory de novo or have
acquired resistance to oestrogen deprivation. The detail of
growth factor receptor kinase–ER interplay remains
controversial in such cells, although it seems likely that there
are subtle differences in pathway detail versus tamoxifen
resistant states.
A new report by Sabnis and coworkers [8] is important not
only because it further adds to our knowledge of growth
factor receptor kinase–ER signalling in experimental acquired
resistance to oestrogen deprivation, but also because it has
successfully demonstrated that targeting with STIs can
indeed enhance the inhibitory effects of endocrine agents in
such cells. In the few long-term oestrogen deprived models
examined to date, increases in HER2, insulin-like growth
factor-1 receptor (with less evidence for EGFR) and
downstream MAPK/PI3K signalling have been implicated.
Such pathways interact with ER in a genomic or nongenomic
manner, and together with adaptive increases in ER can
promote oestrogen hypersensitivity [9-11]. STIs targeting
MAPK kinase (MEK), PI3K and mammalian target of
rapamycin (mTOR); gefitinib at dosages that block HER2;
and the ER downregulator fulvestrant are growth inhibitory.
Sabnis and coworkers [8] now confirm that HER2 and
PI3K/AKT signalling (but not MAPK) is upregulated and
growth contributory in a new model (UMB-1Ca) of acquired
resistance to oestrogen depletion generated from ER-positive
aromatase-transfected MCF-7Ca cells in vitro. Although UMB-
1Ca cells are apparently refractory to oestrogen, tamoxifen
and anastrazole, they contain elevated ER that appears
functional because cell growth can be inhibited by high
fulvestrant concentrations. In addition to direct promotion of
cell survival by AKT, immunoprecipitation studies indicate
crosstalk with ER in UMB-1Ca cells. Excitingly, targeting of
PI3K/AKT signalling or HER2 (using wortmannin or gefitinib,
respectively) restores the antiproliferative activity of
anastrazole or tamoxifen in UMB-1Ca cells, and wortmannin
also improves the inhibitory effects of fulvestrant. In total,
these new data are highly supportive of examining STIs and
their combination with endocrine agents in patients, including
those refractory to oestrogen deprivation.
Conclusion
Although the preclinical and, in general, clinical data available
indicate that growth factor receptor kinase pathways are
important in several forms of antihormone resistant breast
cancer, a number of key issues remain. There are questions
regarding the prominence of these pathways in clinical
acquired resistance, and deciphering of the elusive
mechanisms of interplay with ER signalling is required across
the various endocrine resistant states. Clarification of these
issues through clinical and preclinical studies, like those
reported by Guttierez [6] and Sabnis [8] and their groups, is
essential if we are to interpret adequately the various ongoing
STI trials in clinical breast cancer, allow design of improved
targeting strategies, and better select patients for treatment
by revealing appropriate predictive biomarkers. Because in
parallel with a role in growth these signalling pathways also
appear able to promote invasiveness of endocrine resistant
cells, including UMB-1Ca [8,12], such knowledge may reveal
strategies that ultimately confer major improvements in
patient prognosis.
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